Story excerpt provided by Post-Bulletin.
Written by Jeff Kiger.
The $225 million sale of an Ohio biotech company could be a financial boon for Mayo Clinic.
Assurex Health launched in 2006 with funding from Mayo Clinic Ventures and Mayo Clinic plus the company licensed its premier product, GeneSight Psychotropic test, from Mayo Clinic.
GeneSight is a test that analyzes psychiatric patients’ genes to determine the best antidepressant and antipsychotic drugs to treat the patient. It was developed by the late Dr. David Mrazek, Dr. Dennis O’Kane and Dr. John L. Black.
Click here to read the complete article.
Originally published August 19, 2016.